Outcome and CKD Stage | Adjusted OR | 95% CI | P Value |
Wound Infection | |||
Stage 1 | 1.458 | 1.119–1.900 | 0.00512 |
Stage 2 | 2.218 | 1.780–2.765 | 1.33E−12 |
Stage 3a | 1.577 | 1.048–2.373 | 0.0287 |
Stage 3b | 1.114 | 0.542–2.289 | 0.768 |
Stage 4 | 0.468 | 0.130–1.686 | 0.246 |
Stage 5 | 1.689 | 0.487–5.856 | 0.408 |
Pulmonary Event | |||
Stage 1 | 1.514 | 1.191–1.924 | 0.000704 |
Stage 2 | 1.010 | 0.752–1.356 | 0.944 |
Stage 3a | 1.063 | 0.681–1.661 | 0.786 |
Stage 3b | 1.654 | 0.989–2.766 | 0.0550 |
Stage 4 | 0.843 | 0.398–1.784 | 0.656 |
Stage 5 | 0.811 | 0.276–2.377 | 0.703 |
Venous thromboembolism | |||
Stage 1 | 1.293 | 0.993–1.684 | 0.0561 |
Stage 2 | 1.423 | 1.110–1.825 | 0.00540 |
Stage 3a | 0.624 | 0.336–1.158 | 0.135 |
Stage 3b | 2.209 | 1.306–3.735 | 0.0031 |
Stage 4 | 0.550 | 0.161–1.869 | 0.338 |
Stage 5 | 1.703 | 0.366–7.928 | 0.497 |
MACE | |||
Stage 1 | 1.248 | 0.7977–1.952 | 0.332 |
Stage 2 | 1.148 | 0.775–1.700 | 0.489 |
Stage 3a | 0.929 | 0.507–1.702 | 0.814 |
Stage 3b | 0.127 | 0.017–0.925 | 0.0417 |
Stage 4 | 0.665 | 0.257–1.719 | 0.401 |
Stage 5 | 0.236 | 0.031–1.768 | 0.160 |
Renal event | |||
Stage 1 | 0.773 | 0.320–1.865 | 0.567 |
Stage 2 | 0.561 | 0.228–1.381 | 0.209 |
Stage 3a | 3.873 | 1.993–7.526 | 6.44E−05 |
Stage 3b | 1.922 | 0.944–3.914 | 0.0715 |
Stage 4 | 0.098 | 0.013–0.732 | 0.0235 |
Stage 5 | 6.34E−08 | 0–inf | 0.998 |
Death within 30 d | |||
Stage 1 | 2.134 | 1.528–2.980 | 8.48E−06 |
Stage 2 | 1.252 | 0.814–1.924 | 0.305 |
Stage 3a | 1.650 | 0.772–3.530 | 0.196 |
Stage 3b | 0.973 | 0.331–2.853 | 0.960 |
Stage 4 | 0.612 | 0.170–2.194 | 0.451 |
Stage 5 | 1.78E−07 | 0–inf | 0.986 |
Sepsis | |||
Stage 1 | 0.940 | 0.662–1.335 | 0.731 |
Stage 2 | 2.202 | 1.634–2.967 | 2.09E−07 |
Stage 3a | 0.975 | 0.585–1.626 | 0.925 |
Stage 3b | 1.869 | 1.004–3.479 | 0.0483 |
Stage 4 | 0.940 | 0.360–2.457 | 0.901 |
Stage 5 | 2.296 | 0.750–7.022 | 0.145 |
Urinary tract infection | |||
Stage 1 | 1.050 | 0.775–1.422 | 0.750 |
Stage 2 | 1.535 | 1.208–1.950 | 0.000446 |
Stage 3a | 0.946 | 0.635–1.409 | 0.788 |
Stage 3b | 1.826 | 1.130–2.951 | 0.0138 |
Stage 4 | 1.171 | 0.508–2.699 | 0.711 |
Stage 5 | 2.506 | 0.525–11.946 | 0.249 |
Transfusion within 72 h | |||
Stage 1 | 1.270 | 1.135–1.422 | 2.98E−05 |
Stage 2 | 1.358 | 1.225–1.504 | 5.09E−09 |
Stage 3a | 1.046 | 0.878–1.245 | 0.611 |
Stage 3b | 0.961 | 0.746–1.238 | 0.761 |
Stage 4 | 1.203 | 0.833–1.737 | 0.324 |
Stage 5 | 0.368 | 0.177–0.765 | 0.00738 |
Return to operating room | |||
Stage 1 | 1.186 | 0.973–1.445 | 0.0905 |
Stage 2 | 1.687 | 1.421–2.002 | 2.07E−09 |
Stage 3a | 1.276 | 0.948–1.719 | 0.107 |
Stage 3b | 1.103 | 0.684–1.777 | 0.687 |
Stage 4 | 0.940 | 0.476–1.856 | 0.860 |
Stage 5 | 3.744 | 1.844–7.602 | 0.000258 |
Length of stay ≥10 d | |||
Stage 1 | 0.988 | 0.854–1.145 | 0.882 |
Stage 2 | 1.144 | 0.981–1.334 | 0.0853 |
Stage 3a | 0.970 | 0.750–1.254 | 0.820 |
Stage 3b | 1.031 | 0.728–1.461 | 0.859 |
Stage 4 | 1.024 | 0.659–1.590 | 0.916 |
Stage 5 | 0.876 | 0.464–1.656 | 0.686 |
Abbreviations: CKD, chronic kidney disease; MACE, major adverse cardiovascular event.
Note: Adjusted OR for each postoperative outcome variable stratified by CKD staging. For each CKD stage, multivariate logistic regression modeling used patients without chronic steroid use as the reference group to determine adjusted ORs. Statistical significance was defined as a Bonferroni-adjusted P value ≤0.017.